NCT06359847View on ClinicalTrials.gov

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Differentiated Thyroid Carcinoma
Interventions
DRUG

ST-1898 tablets

Tablets: 5 mg and 40 mg

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Beijing Scitech-Mq Pharmaceuticals Limited

INDUSTRY